Stocks Health care SCYX

NASDAQ · Health care

Scynexis Inc (SCYX)

Scynexis Inc brought in $19.2M of revenue over the twelve months to June 30, 2026, up 489.8% from a year earlier. It posted a net loss of $10.2M. At June 30, 2026 it held $10.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.

Watch SCYX in 60 seconds

Follow SCYX

Free, no password. An email when SCYX files with the SEC.

Key facts about Scynexis Inc

Net worth

Scynexis Inc has a market value (market cap) of $35M at the latest share price, and shareholders' equity of $66.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2025 revenue was $20.6M (+449.9% year on year), with a net loss of $8.6M. Over the 12 months to June 30, 2026: revenue $19.2M, net loss $10.2M.

Cash flow

In fiscal 2025 operations used $5.3M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

Next earnings report

Scynexis Inc's next report was expected around November 4, 2026 and is not on file with the SEC yet.

What Scynexis Inc does

Scynexis Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SCYX.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where SCYX ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Scynexis Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 28, 2026
   Material agreement8-KSCYNEXIS secured a contract with BARDA providing up to $214 million in potential funding to develop its antifungal candidate SCY-247.
2. September 22, 2026
   Executive or director change8-KSCYNEXIS appointed Steven K. Burke, M.D., to its Board of Directors effective September 18, 2026.
3. September 10, 2026
   Executive or director change 8-K
4. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
5. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
6. August 12, 2026
   Passive stake (5% or more) SCHEDULE 13G
7. August 10, 2026
   Employee stock plan registration S-8
8. August 10, 2026
   Quarterly report 10-Q · period to June 30, 2026Revenue fell 83% to $235K versus the same quarter last year; diluted EPS $0.63 versus -$1.11.
9. June 26, 2026
   Bylaws or fiscal year changed 8-K
10. May 29, 2026
    Bylaws or fiscal year changed 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 22, 2026. Insider transactions on SEC

Insider trades

What the people running Scynexis Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns SCYX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Kingdon Capital Management, L.L.C. 0% (February 17, 2026).

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 39 managers reported a position.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

9 insiders reported holding 2,395,543 shares in total, about $8.4M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about SCYX

What does Scynexis Inc do?

Scynexis Inc is a company in the Health care sector, listed on NASDAQ as SCYX. Its shares trade on NASDAQ under the ticker SCYX.

What is Scynexis Inc's net worth?

Scynexis Inc has a market value (market cap) of $35M at the latest share price, and shareholders' equity of $66.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Scynexis Inc profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $10.2M on revenue of $19.2M.

How much revenue does Scynexis Inc make?

Over the twelve months to June 30, 2026 Scynexis Inc reported revenue of $19.2M. That is 489.8% more than a year earlier.

When did Scynexis Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 28, 2026.

When is Scynexis Inc's next earnings report?

Scynexis Inc's next report was expected around November 4, 2026 and is not on file with the SEC yet.

Similar companies

Compare SCYX with

Compare SCYX with any company

Follow SCYX

Get an email when Scynexis Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow SCYX

Free, no password. An email when SCYX files with the SEC.

Where the numbers come from

Financial figures are the values Scynexis Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.